Cargando…
Long-Term Management of Orbital and Systemic Reactive Lymphoid Hyperplasia with Rituximab
Rituximab, a monoclonal antibody to the B cell marker CD20, is becoming increasingly popular in the treatment of various orbital disorders. In this university-based interventional case series, we describe two patients with bilateral orbital and extra-orbital reactive lymphoid hyperplasia (RLH) treat...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519137/ https://www.ncbi.nlm.nih.gov/pubmed/23248552 http://dx.doi.org/10.4103/0974-9233.102770 |